EN DE

PT Ekadharma International Tbk, (EKAD) Fair Value & Analysis

Basic Materials · ID · Market cap 594B IDR

PE PT Ekadharma International Tbk, EKAD · JK
Price178.00 IDR
Fair Value270.06 IDR
Upside+51.7%
Quality63/100
Watch PT Ekadharma International Tbk, for free, get notified when fair value or trend changes. Watch for free
Weak Growth
Thin margins · 9.2% net margin
Low debt · generates free cash flow
Ranks above peers (8/11)
Narrow moat 40/100
Evidence: High Range 206.64 IDR – 333.47 IDR Share as image

Fair value as of: Jul 17, 2026

From 23 valuation models · updated 24 days ago

Fair value updated Jul 17, 2026, revised from 295.81 IDR to 270.06 IDR (−8.7%) since Jun 24, 2026. Share price +4.7% over the past month.

A solid business, screening 52% undervalued on our models.

What matters now

  • The price is below even our cautious bear case (206.64 IDR). The market is more pessimistic than our downside scenario.
  • Solid quality (63/100) at a price below fair value, the discount is the argument here, not the business quality.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

273.71 IDR 153.00 IDR Fair Value 270.06 IDR Feb 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 17, 2026.

How to read this chart

60‑month range 153.00 IDR – 273.71 IDR · fair‑value band 206.64 IDR – 333.47 IDR · the 178.00 IDR price screens below the 270.06 IDR fair value. Dashed = 300-day average. As of Jul 17, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

PT Ekadharma International Tbk, (EKAD) currently trades at 178.00 IDR, while our model-based Fair Value estimate is 270.06 IDR, implying the stock looks roughly 51.7% undervalued today. The Quality Score stands at 63/100 (solid quality), in the Basic Materials sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.

Over the trailing twelve months, PT Ekadharma International Tbk, generated revenue of 543B IDR at a net margin of 9.2%. Revenue grew 10.7% year over year. It earns a return on equity of 4.0%. The balance sheet holds a net cash position of 57.3B IDR. Fundamentals as of Jul 17, 2026

Our scenario range runs from 206.64 IDR (bear case) to 333.47 IDR (bull case); at 178.00 IDR, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 17% below its 52-week high and 24% above its 52-week low, currently below its 200-day average. For context, the median of 10 Basic Materials peers we cover trades at -58% fair-value upside, at 52%, EKAD screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF 331.44 IDR 470.95 IDR 673.73 IDR 80
Residual Income 268.56 IDR 269.39 IDR 252.38 IDR 76
Rev-Margin DCF 210.12 IDR 290.97 IDR 380.51 IDR 74
All 23 models by family
DCF Models
FCF DCF 322.24 IDR 472.81 IDR 702.10 IDR 38
Owner Earnings 210.35 IDR 304.63 IDR 448.19 IDR 31
5Y Revenue Exit 210.12 IDR 286.82 IDR 379.58 IDR 39
5Y EBITDA Exit 247.00 IDR 353.20 IDR 471.33 IDR 41
5Y P/E Exit 263.96 IDR 383.72 IDR 503.56 IDR 38
10Y Revenue Exit 243.42 IDR 321.31 IDR 415.66 IDR 36
10Y EBITDA Exit 271.24 IDR 367.49 IDR 484.81 IDR 37
10Y P/E Exit 282.13 IDR 388.73 IDR 509.10 IDR 35
Earnings-Based
Graham-Dodd 103.20 IDR 259.98 IDR 337.66 IDR 54
PEG = 1.0 47.91 IDR 68.45 IDR 88.98 IDR 46
EPV 143.69 IDR 164.99 IDR 183.93 IDR 59
Multiples
P/E Multiple 239.03 IDR 318.71 IDR 398.38 IDR 63
P/S Multiple 193.50 IDR 258.00 IDR 322.50 IDR 58
P/B Multiple 193.50 IDR 258.00 IDR 322.50 IDR 55
EV/EBIT 213.21 IDR 276.62 IDR 340.04 IDR 53
EV/EBITDA 232.53 IDR 302.38 IDR 372.23 IDR 54
EV/Revenue 158.75 IDR 216.94 IDR 275.13 IDR 43
Asset-Based
NCAV (Graham) 175.77 IDR 235.53 IDR 351.54 IDR 50
Growth DCF
Growth DCF 331.44 IDR 470.95 IDR 673.73 IDR 80
Rev-Margin DCF 210.12 IDR 290.97 IDR 380.51 IDR 74
Economic Profit
Residual Income 268.56 IDR 269.39 IDR 252.38 IDR 76
ROIC Compounder 143.69 IDR 164.99 IDR 183.93 IDR 72
Growth Earnings
Growth-Adj P/E 184.63 IDR 263.75 IDR 342.88 IDR 68

Widest divergence: DCF Models (353.20 IDR) versus Earnings-Based (164.99 IDR). Highest evidence: Growth DCF (80).

Notify me when EKAD reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 543B IDR
Revenue growth (YoY) +10.7%
Net margin 9.2%
Return on equity 4.0%
Free cash flow 91.8B IDR FY2025
P/E ratio 1.2
More key figures
Operating margin 9.2%
EPS (TTM) 146.27 IDR
EPS growth (YoY) -42.6%
Net cash 57.3B IDR FY2025

Figures from reported company fundamentals · as of Jul 17, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 63/100

Of which business quality 64 · Market factors (momentum, volatility) 58

Profitability 30
Margins and returns on capital today
Quality Growth 25
Are margins and returns improving?
Cashflow 82
Earnings quality: real cash, not paper profit
Fin. Strength 84
Balance sheet, leverage, solvency risk
Investment 83
Disciplined investing over empire-building
Low Volatility 93
Calm price path (market factor)
Momentum 43
Price trend over the last 3–12 months (market factor)
52W Momentum 43
Distance to the 52-week high (market factor)
Net Issuance 82
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

PT Ekadharma International Tbk, together with its subsidiaries, engages in manufacturing and sale of self-adhesive tapes and related supplementary materials in Indonesia and Malaysia. It operates through Sticking Plaster and Others segments.

Full company description

PT Ekadharma International Tbk, together with its subsidiaries, engages in manufacturing and sale of self-adhesive tapes and related supplementary materials in Indonesia and Malaysia. It operates through Sticking Plaster and Others segments. The company offers lint roller, accessories, industrial tape, packaging products, and cutters; cloth tape/masking tape products; reflective, PVC electrical, and aluminum foil tape; cling wrap, and aluminum foil; kraft tape; OPP tape, including custom, printed, and OPP color tape; and air column bag products. It also engages in general trading business. The company sells its products under the Daimaru, SUPERFIX, and BESTPACK brands. The company was formerly known as PT Ekadharma Widya Grafika and changed its name to PT Ekadharma International Tbk in 2006. The company was founded in 1981 and is headquartered in Tangerang, Indonesia. PT Ekadharma International Tbk is a subsidiary of PT Ekadharma Inti Perkasa.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

PT Ekadharma International Tbk, reported revenue of 530B IDR in FY2025 versus 630B IDR in FY2021, a compound −4.2%/yr. Reported net income was 53.0B IDR in FY2025, compounding −15.6%/yr from FY2021.

Growth Quality 40/100
Revenue growth is weak, negative or inconsistent.
Latest Revenue (FY 2025)
530B IDR
Latest YoY
−0.2%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−4.8%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−4.6%
Avg. growth/yr (25Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+7.7%
Revenue −4.2%/yr
FY21 630B IDR
FY22 614B IDR
FY23 518B IDR
FY24 530B IDR
FY25 530B IDR
Net income −15.6%/yr
FY21 104B IDR
FY22 76.7B IDR
FY23 71.9B IDR
FY24 64.4B IDR
FY25 53.0B IDR
Character of growth · EPS growth decomposed (2014-2025) +0.9 % p.a.
Revenue per share −0.3 pp

of which total revenue −0.3 pp · buybacks/dilution +0.0 pp

EBIT margin −3.0 pp
Tax rate +1.4 pp
Residual (interest, one-offs) +2.8 pp

Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).

Watch EKAD: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "PT Ekadharma International Tbk, Fair Value". https://www.fairvalue-calculator.com/stock/EKAD

Peer Group

Specialty Chemicals · 669 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 63 · Top 25%
Fair Value upside +52% · Top 25%
Return on equity (TTM) 4% · Below median
Return on assets 2% · Below median
Net margin (TTM) 9% · Above median
Operating margin (TTM) 9% · Above median
Revenue growth 11% · Above median
Dividend yield (TTM) 0.0% · Bottom 25%

Valuation Multiples vs Specialty Chemicals median · lower = cheaper

P/E (TTM) 1.2× · Cheaper than 75% of peers
P/FCF 0.0× · Cheaper than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 100 · sector 0
FUTURE 54 · sector 19
PAST 16 · sector 23
HEALTH 100 · sector 94
DIVIDEND 0 · sector 25

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Specialty Chemicals stocks, each showing price versus our Fair Value estimate (as of Jul 17, 2026).

Stock Price Fair Value vs Fair Value
Linde plc LIN $489.98 $222.03 -55%
Nan Ya Plastics Corporation 1303 181.50 TWD 255.83 TWD +41%
Wanhua Chemical Group 600309 ¥70.04 ¥68.03 -3%
Novozymes A/S NSISB kr 428.20 kr 179.66 -58%
Asian Paints Limited ASIANPAINT ₹2,689 ₹668.81 -75%
Solar Industries India Limited SOLARINDS ₹18,236 ₹2,793 -85%
Pidilite Industries Limited PIDILITIND ₹1,560 ₹351.84 -77%
PT Chandra Asri Pacific Tbk TPIA 1,805 IDR 2,888 IDR +60%
Linde India Limited LINDEINDIA ₹7,115 ₹757.93 -89%
Berger Paints India Limited BERGEPAINT ₹493.70 ₹164.29 -67%

Compare PT Ekadharma International Tbk, with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Basic Materials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is PT Ekadharma International Tbk, (EKAD) overvalued or undervalued?
As of Jul 17, 2026, our model estimates a fair value of 270.06 IDR versus a price of 178.00 IDR, about +52% (undervalued).
What is the fair value of EKAD?
Our model-based fair value for PT Ekadharma International Tbk, is 270.06 IDR (as of Jul 17, 2026), built from audited fundamentals. The current price is 178.00 IDR.
What is the quality score of EKAD?
PT Ekadharma International Tbk, has a Quality Score of 63/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of PT Ekadharma International Tbk, (EKAD)?
PT Ekadharma International Tbk, reported trailing-twelve-month revenue of about 543B IDR (latest available figure, as of Jul 17, 2026).
What is the net profit margin of EKAD?
The net profit margin of PT Ekadharma International Tbk, is about 9.2%, meaning it keeps roughly 9.2% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track PT Ekadharma International Tbk, and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.